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HOGA1Glyoxylate detoxiﬁcation is an important function of human peroxisomes. Glyoxylate is a highly reactive
molecule, generated in the intermediary metabolism of glycine, hydroxyproline and glycolate mainly. Glyox-
ylate accumulation in the cytosol is readily transformed by lactate dehydrogenase into oxalate, a dicarboxylic
acid that cannot be metabolized by mammals and forms tissue-damaging calcium oxalate crystals. Alanine-
glyoxylate aminotransferase, a peroxisomal enzyme in humans, converts glyoxylate into glycine, playing a
central role in glyoxylate detoxiﬁcation. Cytosolic and mitochondrial glyoxylate reductase also contributes
to limit oxalate production from glyoxylate. Mitochondrial hydroxyoxoglutarate aldolase is an important en-
zyme of hydroxyproline metabolism. Genetic defect of any of these enzymes of glyoxylate metabolism results
in primary hyperoxalurias, severe human diseases in which toxic levels of oxalate are produced by the liver,
resulting in progressive renal damage. Signiﬁcant advances in the pathophysiology of primary hyperoxalurias
have led to better diagnosis and treatment of these patients, but current treatment relies mainly on organ
transplantation. It is reasonable to expect that recent advances in the understanding of the molecular mech-
anisms of disease will result into better targeted therapeutic options in the future. This article is part of a Spe-
cial Issue entitled: Metabolic Functions and Biogenesis of peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Glyoxylate is a two-carbon (C2) keto-acid generated by intermediary
metabolism, with glycine, hydroxyproline and glycolate as the best
known sources in humans. Glyoxylate is a highly reactive aldehyde
that is readily catalyzed by various dehydrogenases and oxidases, includ-
ing lactate dehydrogenase (LDH), which converts it into oxalate, an end
product of metabolism in mammals that has to be eliminated with the
urine and tends to precipitate as tissue-damaging calcium oxalate.
Since LDH is quite abundant in the hepatocyte cytosol and vertebrates
lack the ability to use C2 compounds to produce TCA cycle intermediates
via the glyoxylate shunt, most of the glyoxylate generated must be me-
tabolized within organelles such as the peroxisome and mitochondria
in order to limit oxalate production. To further control the levels of oxa-
late produced, cytosolic glyoxylate reductase (GRHPR) competes with
LDH for glyoxylate, reducing it to glycolate, a highly soluble C2molecule
(Fig. 1).
In human hepatocytes, abundant alanine-glyoxylate aminotrans-
ferase (AGT) makes the peroxisome [1] an efﬁcient ‘glyoxylate sink’,
converting glyoxylate in glycine. Glyoxylate can be imported fromrotein encoded by the AGXT gene. H
olic Functions and Biogenesis of pe
34 922319412.
rights reserved.the cytosol/mitochondria and it can also be produced in the peroxi-
some by either D-amino acid oxidase (DAO) or hydroxyacid oxidase
(HAO1) (glycolate oxidase), using glycine or glycolate as substrate,
respectively. The peroxisome membrane is permeable to glycolate,
glyoxylate and other small hydrophilic solutes, largely due to the
presence of the channel-forming protein PXMP2 [2]. This, combined
with the fact that AGT can tolerate high glyoxylate concentrations
without showing inhibitory action on the forward reaction [3] make
the peroxisome a glyoxylate detoxifying compartment that shields
the surrounding cytoplasm from glyoxylate accumulation and sec-
ondary oxalate production.
Mitochondria also play an important role in glyoxylatemetabolism
[4,5], mainly due to their capacity to metabolize hydroxyproline,
through a series of four enzymatic reactions [6]. Collagen is a major
constituent of extracellular matrix. Posttranslational modiﬁcation of
collagen by proline hydroxylase during the biosynthesis and matura-
tion of collagen contribute to the stability of the collagen triple helix.
Upon collagen turnover, the 4-hydroxyproline released cannot be reu-
tilized and is degraded. Theﬁrst two reactions of the pathway are anal-
ogous to those of proline degradation, but the ﬁrst enzyme ofowever, we will use AGT in this review to refer to the protein encoded by the gene AGXT
roxisomes in Health and Disease.
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Fig. 1. Glyoxylate detoxiﬁcation pathway in human hepatocytes. Simpliﬁed pathways involving glycine, glycolate and hydroxyproline as the main sources of glyoxylate. Peroxisom-
al glyoxylate is detoxiﬁed by AGT, while mitochondrial and cytosolic glyoxylate is reduced to glycolate by GRHPR, preventing excessive oxidation to oxalate by LDH. Hydroxyproline
metabolism results in the production of 4-hydroxy-2-oxoglutarate that is normally split into glyoxylate and pyruvate by HOGA1. PyrrOHcarbox=pyrroline-5-carboxylate; H-
Glu=4-hydroxy-glutamate; HO-Glu=4-hydroxy-2-oxoglutarate.
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proline oxidase. Indeed, patients deﬁcient in proline oxidase do not
show elevated 4-hydroxyproline levels, while free hydroxyproline,
but not proline, accumulates in the plasma and urine of individuals
with hydroxyproline oxidase deﬁciency. The last step of the pathway
is also speciﬁc to hydroxyproline degradation and involves the cleav-
age of 4-hydroxy-2-oxoglutarate (2-keto-4-hydroxyglutarate) into
glyoxylate and pyruvate by 4-hydroxy-2-oxoglutarate aldolase
(HOGA1). The glyoxylate can then be converted to glycolate by
GRHPR. Since collagen contains ~15% hydroxyproline, its turnover
results in an estimated release of 300–450 mg hydroxyproline a
day, accounting for the daily production of 180–240 mg glyoxylate
[7,8].
The glyoxylate detoxiﬁcation pathway reﬂects the evolutionary
origins of metabolic compartmentalization [9], and the subcellular
distribution of its key enzymes has been under evolutionary pressure.
Diet must have been an important component, since glycolate is
abundant in vegetables while hydroxyproline is abundant in meat.
The subcellular distribution of AGT has been thoroughly analyzed
in numerous mammals, and it has been shown to vary between per-
oxisomes and mitochondria in different species [10]. Signiﬁcant cor-
relation between AGT distribution and diet was found [11]:
mitochondrial in carnivores, peroxisomal in herbivores, and both mi-
tochondrial and peroxisomal in omnivores, suggesting that the vari-
able subcellular localization of AGT results from dietary selection
pressure.
The relevance of glyoxylate detoxiﬁcation to human health is ex-
empliﬁed by the devastating consequences of inherited mutations in
genes coding for key enzymes in this pathway (Fig. 1), resulting in
mendelian diseases characterized by high oxalate content in the
urine: primary hyperoxalurias (PHs).2. Primary hyperoxalurias
PHs are rare inborn errors of glyoxylate metabolism that result in
high oxalate production mainly by the liver [12–14]. Oxalate does not
seem toxic to hepatocytes, but since it cannot be metabolized in
mammals, it can only be ﬁltered at the glomerulus and also secreted
by the renal tubules (and to some extent the bowel also), with uri-
nary excretion levels>0.5 mmol/1.73 m2 per day (typically>1 m-
mol/1.73 m2) in PH patients (normal oxalate excretionb0.45 mmol/
1.73 m2 per day). The kidneys undergo progressive deterioration
due to calcium oxalate deposition: urolithiasis, nephrocalcinosis and
end stage renal disease (ESRD). The parenchymal deposition of oxa-
late (nephrocalcinosis) induces interstitial inﬂammation and ﬁbrosis
that result in progressive loss of renal function. The endogenous over-
production of oxalate, with normal dietary oxalate absorption [15],
sets these mendelian disorders apart from secondary hyperoxalurias,
which result from increased oxalate absorption in the gut. Secondary
hyperoxalurias tend to be milder (b0.8 mmol/1.73 m2 per day) and
are usually a consequence of gastrointestinal diseases frequently as-
sociated to fat malabsorption: inﬂammatory bowel diseases, cystic ﬁ-
brosis, bariatric surgery or short bowel syndrome [16]. However,
severe cases of secondary hyperoxaluria can also lead to ESRD and
systemic oxalosis.
The three genetic defects currently known to cause PH are
inherited with autosomal recessive pattern. The genes involved
are alanine-glyoxylate aminotransferase (AGXT, at 2q37.3,
MIM*604285), for PH type I (PH1, MIM#259900), glyoxylate reduc-
tase/hydroxypyruvate reductase (GRHPR, at 9q12, MIM*604296), for
PH type II (PH2, MIM#260000) and 4-hydroxy-2-oxoglutarate al-
dolase (HOGA1, also known as DHDPSL, at 10q24.2, MIM*613597),
for PH type III (PH3, MIM#613616). Most of the PH families can
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with primary hyperoxaluria for which the genetic defect has not
been found yet.
Around 80% of PH patients suffer PH1, a peroxisomal disease and
the most severe PH type, usually resulting in ESRD at some point, al-
though with a wide range of severity. At ESRD, the build-up of oxa-
late in the body (known as oxalosis) quickly results in bone, heart,
skin and retinal complications and, unless liver-kidney transplanta-
tion is performed, death in most patients [17–19]. Given its statistical
predominance, most epidemiological studies on PH, essentially refer
to PH1.
PH has an estimated prevalence ranging from 1 to 3 per million
population and an estimated incidence rate of ~1:100,000 live births
per year in Europe [20–22], although the exact prevalence is difﬁcult
to assess, due to suspected underdiagnosis, with symptoms attributed
to common kidney stone disease. The most comprehensive attempts
to estimate the true incidence of the disease [22] have resulted in
higher incidence rates than previously reported. Higher rates have
also been found in historically isolated populations, like the Canary
Islands, due to founder effect [19]. Although PH accounts for a little
less than 1% of pediatric ESRD population in registries from developed
countries [23], the disease is more prevalent in countries where con-
sanguineous marriages are common. Approximately 10% of Kuwaiti
children and 13% of Tunisian children with ESRD have been reported
to suffer PH [24,25].
2.1. Primary hyperoxaluria type I
PH1 is caused by deﬁcient or mistargeted AGT [26], a liver-speciﬁc
enzyme that, in humans, is normally located in the peroxisomes only.
From the early descriptions of PH1, it was reported that the majority
of patients had glycolic aciduria and hyperoxaluria [27]. AGT catalyzes
the transamination between L-alanine and glyoxylate, to produce pyru-
vate and glycine in the presence of pyridoxal 5′-phosphate (PLP) as co-
factor, a reaction largely shifted to the formation of pyruvate and
glycine [3].
AGXT cDNA was independently cloned by two groups [28,29],
using probes from the orthologous rat gene [30]. The gene has 11
exons and spans ~10 kb [31], resulting in a 1.7 kb mRNA with a cod-
ing sequence of 1176 bp. The gene product AGT is a homodimeric
protein, each 43 kDa subunit containing 392 amino acids and holding
one molecule of PLP as cofactor [32]. The main N-terminal domain
contains most of the catalytic active site, the cofactor-binding site,
and the dimerization interface. The smaller C-terminal domain is
known to interact with the peroxisomal receptor PEX5, targeting
the dimer to the peroxisome. AGT, carrying a non-canonical peroxi-
somal targeting sequence (PTS1), is among the peroxisomal proteins
with the weakest afﬁnities for PEX5 [33]. An ancillary sequence sur-
rounding amino acids 324–345 has been proposed to help the perox-
isomal targeting of AGT [34]. A recently released crystal structure of
the AGT in complex with the PTS1-binding domain of PEX5 (PDB:
3IMZ) also conﬁrmed that residues 303–306 and 327–330 are largely
buried upon binding. In fact, AGT binds to PEX5 with ~10-fold higher
afﬁnity than its PTS1 octapeptide, showing the functional role of this
ancillary sequence in PEX5 binding (unpublished).
The 3-D structure of AGT (PDB: 1H0C) [32] has provided impor-
tant information to better understand the function of the protein
and the effect of changes in amino acid that account for a majority
of the PH1 mutations. Important contributions to the physico-
chemical and enzymatic properties of recombinant AGT and some of
its common variants have also been reported recently [35].
More than 150 mutations have been described for AGXT, which is
expressed only in the liver, and they have been summarized recently
[36]. Missense mutations are common, followed by small insertion/
deletions (indels). Wild type AGXT comes in two polymorphic vari-
ants, the most frequent major haplotype (refseq NM_000030) andthe less frequent minor haplotype, carrying two single amino acid
substitutions (P11L and I340M) among other genomic changes in
strong linkage disequilibrium. Since these two polymorphisms are
quite old, most of the individual PH1 mutations described are typical-
ly found in either the major or minor haplotype, but rarely in both.
This fact can help in the clinic, when searching for mutations in new
PH1 cases [37]. The minor haplotype (simply deﬁned by the refSNP
rs34116584, Pro11Leu), with an allelic frequency of 0.1–0.2 in west-
ern countries and average heterozygosity around 0.2, does not cause
PH1 by itself, but it is known to act synergistically with the deleteri-
ous effects of several common mutations [13,38].
2.1.1. Molecular mechanisms of disease
AGXT mutations result in severe reductions of AGT enzymatic ac-
tivity in the peroxisome, with a relatively wide range of residual ac-
tivity, depending on the mutations present in both alleles [39].
Although AGT functions as a dimer, all the mutations described so
far are related to loss-of-function, with recessive pattern of inheri-
tance, without clear evidence of potential dominant negative effect.
Small indels are responsible for some PH1 cases, most notably
c.33dupC, the most common mutation of the major haplotype, with
the predicted consequence of early stop codon and non-sense medi-
ated mRNA decay. But the majority of PH1 alleles are missense muta-
tions, with prevalent amino acid changes that make many PH1 cases
good examples of conformational disease. Four main molecular
mechanisms have been described to explain the consequences of mu-
tations in AGXT: mitochondrial mistargeting, protein aggregation, cat-
alytic defects and synthesis defects.
2.1.1.1. Mitochondrial mistargeting. One of the best studied aspects of
AGT is its subcellular localization in various organisms. In mice and
rats, AGT is present both in the mitochondria and peroxisomes,
while in humans and rabbits, it is exclusively located in the peroxi-
some [10]. About a third of PH1 alleles involve the G170R substitu-
tion, in the minor haplotype, which is responsible for mitochondrial
mistargeting of the gene product, becoming one of the best known
examples of human mutations resulting in mistargeting as the main
mechanism of disease [40–42]. In addition to G170R, the missense
mutation F152I, also in the minor haplotype was found to cause
AGT mistargeting to the mitochondria instead of the peroxisome,
leaving the latter organelle devoid of its glyoxylate detoxifying capa-
bility. The polymorphism P11L of the minor haplotype plays a crucial
role for G170R to result in mitochondrial mistargeting [43], which has
been associated to impaired folding efﬁciency to form functional di-
mers, therefore preventing the peroxisomal import of folded AGT
[44]. The mutant protein, particularly in the apoprotein form, devoid
of PLP cofactor, has been shown recently to have much reduced kinet-
ic stability in vitro, and enhanced interaction with molecular chaper-
ones HSC70 and HSP90 in cell-free assays [45], favoring the
presentation of partially folded protein to the mitochondrial import
machinery. It has also been shown that the other mistargeting muta-
tion, F152I in the minor haplotype, displays substantial kinetic desta-
bilization as apoprotein [46]. Like in other conformational diseases,
the partition of mutant AGT between folding into dimers, with subse-
quent peroxisomal import, and the presentation of partially folded
states to the mitochondrial import machinery is likely to depend on
various factors in the proteostasis network [47], which are the subject
of current investigation.
Protein aggregation is a relatively frequent outcome of missense
mutations in conformational diseases [48]. Several of the most fre-
quent PH1 mutations of the minor haplotype, such as G41R [41] and
I244T [38], are known to display protein aggregation. The P11L poly-
morphismwas also found to play a crucial role for the I244T mutation
to result in a conformationally unstable protein, sensitive to proteo-
lytic cleavage and prone to aggregation [38], while the G41R
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conformational instability as well [49].
Catalytic defects are a common mechanism of disease in inborn er-
rors of metabolism involving enzyme-coding genes. Fine enzymatic
characterization of several PH1 missense mutations (G82E, G41R,
F152I) have demonstrated signiﬁcant alterations in their perfor-
mance, including strong decreases in catalytic efﬁciency and reduced
binding afﬁnities for PLP and PMP cofactors [35].
Synthesis defects are mainly represented by small indels with sec-
ondary shift in the reading frame and early stop codons. The most
common mutation in this group is c.33dupC, the main mutation of
the major haplotype, present in around 13% PH1 alleles. The stretch
of repeated C at the beginning of the coding sequence seems to repre-
sent a hotspot for polymerase slippage, where in addition to
c.33dupC, c.33delC and c.32_33delCC have also been found [50]. In
fact, c.33dupC is the only change for which clear evidence of de
novomutation has been reported [51]. Reading frame shifts frequent-
ly lead to the appearance of premature stop codons a few bases
downstream, and the presence of stop codons in the ﬁrst few exons
normally leads to transcript degradation due to nonsense-mediated
mRNA decay [52]. We could also include in this category a large pro-
portion of the reported splicing mutations and occasional missense
mutations leading to highly unstable protein that is degraded rapidly,
such as S205P [53].
Other mechanisms are involved in a small proportion of PH1
patients, but they also contribute to a better understanding of
the disease [54]. Particularly interesting are the cases of Zellweger
spectrum disorders (ZSDs), characterized by a deﬁcient peroxisom-
al assembly and generalized loss of peroxisomal functions. Al-
though most peroxisomal enzymes are unstable in the cytosol of
ZSD patients, AGT and a few other enzymes remain stable. Howev-
er, when carefully examined, most of these patients do develop
hyperoxaluria, underscoring the importance of the compartmental-
ization of AGT in human peroxisomes in order to achieve proper
glyoxylate detoxiﬁcation [55].
Deeper understanding of the molecular mechanisms of disease
not only helps derive potential genotype–phenotype correlations
but also guides targeted therapeutic approaches (see below).
Genotype–phenotype correlations have been described for some
mutations of the AGXT gene [13,56,57], but the wide allelic hetero-
geneity limits this type of analysis to the most common mutations.
The use of international registries will power this approach to
levels that cannot be achieved by single center studies. Signiﬁcant
environmental inﬂuences and the potential effect of genetic
modiﬁers also play an important role, to the point that siblings
who share the same genotype could have very different clinical
phenotypes [58].2.2. Primary hyperoxaluria type II
PH2, accounting for around 10% of PH cases, is caused by deﬁcient
glyoxylate reductase–hydroxypyruvate reductase (GRHPR). A deﬁcit
in hydroxypyruvate reductase (HPR) activity as a cause of a new PH
variant was ﬁrst reported in 1968 [27], and it later became evident
that the deﬁciency in glyoxylate reductase (GR) activity, catalyzed
by the same protein, was most likely responsible for the hyperoxa-
luria in this disorder [59]. The lack of GRHPR activities in PH2 patients
leads to increases in urinary oxalate and L-glycerate excretion (hence
the term L-glyceric aciduria used in the ﬁrst report) (Fig. 1). PH2 pa-
tients suffer less severe elevations of oxalate in the urine than PH1,
and their progression to ESRD occurs in a minority of cases. GRHPR
is abundant in hepatocytes, and the liver is the main source of oxalate
in PH2, but GRHPR is also expressed to some extent in many tissues
[60], and its expression in renal tubules is likely to contribute signiﬁ-
cantly to the mechanisms of kidney damage in PH2.The GRHPR gene is located on chromosome 9 (9q12) and consists
of 9 exons, with various mRNA species detected, which encode a 328
amino-acid protein that forms ~73 kDa homodimers. Two groups ﬁrst
identiﬁed mutations of this gene as cause of PH2 [61,62], and
detected GR, HPR and D-glycerate dehydrogenase (D-GDH) activities
in the wild-type gene product. The GRHPR protein can be detected
both in cytosolic and mitochondrial fractions, although no clear
mitochondrial-targeting sequence (MTS) is present at the N-
terminus and alternative routes to the classical presequence-
mediated mitochondrial import might be involved.
The structural information derived from crystallized GRHPR
has allowed a better understanding of its substrate speciﬁcity,
NADPH binding, dimerization and other functional aspects of
this protein [63].
A current PH mutation database [50] includes less than 30 differ-
ent PH2mutations of all types, expected to result in loss of protein ex-
pression or catalytic activity. There is a high proportion of small
indels, with a single mutation in exon 2, c.103delG, accounting for
about 40% of PH2 alleles in populations of north European descent
[64,65]. Another common small deletion at the exon/intron 4 bound-
ary, c.403_404+2delAAGT, which results in missplicing, is also rela-
tively frequent (18% of PH2 mutations), while few missense
mutations have been reported in more than one family.
The 3D structure of GRHPR has been useful to understand the
mechanisms involved in the reported missense mutations with re-
duced catalytic activity. Among these, G160R and G165D involve res-
idues in the co-enzyme binding groove, M322R most likely
destabilizes the channel leading to the active site, and two substitu-
tions at R302 (R302H and R302C) disrupt the interactions with a
water molecule and residues S296 and W141 from the adjacent sub-
unit that control substrate access to the active site [63].2.3. Primary hyperoxaluria type III
PH3 accounts for around 10% of PH cases and it is caused by deﬁ-
cient 4-hydroxy-2-oxoglutarate aldolase (HOGA1), the mitochondrial
enzyme that cleaves 4-hydroxy-2-oxoglutarate into pyruvate and
glyoxylate, the last step of the hydroxyproline degradation pathway
[8]. Since its recent description, the presence of HOGA1 mutations is
being investigated in all non-PH1/PH2 patients and PH3 is becoming
more frequent than PH2 as a cause of primary hyperoxaluria. PH3 pa-
tients show a wide range of oxalate elevations in the urine, and
HOGA1 mutations are being found even in patients with milder
hyperoxaluria. PH3 progression to ESRD has not been reported. Deﬁ-
cient HOGA1 activity in PH3 patients most likely results in increases
in 4-hydroxy-2-oxoglutarate, which could be transformed into glyox-
ylate by cytosolic aldolases [66], where glyoxylate is later trans-
formed into oxalate by LDH (Fig. 1). HOGA1 is abundant in
hepatocytes, and the liver is the main source of oxalate in PH3, but
HOGA1 is also present in signiﬁcant amounts in the kidney, which is
likely to contribute signiﬁcantly to the mechanisms of urolithiasis
and renal disease in PH3.
The HOGA1 gene is located on chromosome 10 (10q24.2) and con-
sists of 7 exons, with a main 2.5 kb mRNA transcript in the liver,
which encodes a 327 amino-acid protein that forms ~72 kDa dimers
and ~144 kDa tetramers. Although extensive work had been done
on the biochemistry of hydroxyproline metabolism for decades [8],
and HOGA1 proteins had been puriﬁed from mammalian liver and
kidney [67,68], it was the detailed genetic analysis of a few PH fami-
lies in which both AGXT and GRHPRmutations had been ruled out that
recently identiﬁed HOGA1 as the gene responsible for PH3 [69]. Once
established that HOGA1mutations could account for many of the non-
PH1/PH2 cases, the work could proceed quickly to ﬁnd new muta-
tions in this well-annotated gene among the DNA samples from
hyperoxaluric patients without mutations in either AGXT or GRHPR,
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lithiasis [66].
The HOGA1 protein is synthesized with an N-terminal MTS of 25
residues, which is cleaved after import in the mitochondria. The
structural information derived from crystallized HOGA1 [70] has en-
abled a deeper understanding of the type I aldolase reaction involved,
identifying key interactions for substrate binding, deﬁnition of the ac-
tive site and other functional aspects of this protein. With this struc-
tural background, faster and more accurate predictions of the
consequences of sequence variants currently detected among non-
PH1/PH2 patients will be possible.
In addition to the exon 7 in-frame deletion c.944_946delAGG,
common among the Ashkenazi Jewish patients, that played an impor-
tant role in the identiﬁcation of the gene responsible for PH3, several
missense mutations have been identiﬁed recently [66] [Beck et al.,
Rumsby et al., personal communication]. In line with the autosomal
recessive pattern of inheritance, the consensus is emerging that PH3
mutations convey loss of function, with proteins deﬁcient in either
dimer/tetramer formation, stability or catalytic activity.
3. Tissue damage in PH1
Elevated oxalate has a major effect on calcium oxalate supersatu-
ration, resulting in the formation of calcium oxalate (CaOx) crystals
(both monohydrate -COM- and dyhydrate -COD-). CaOx crystals not
only aggregate in the urinary space producing stones (urolithiasis)
but they also interact with the renal tubule epithelium and deposit
into the renal interstitium (nephrocalcinosis), where they induce
strong inﬂammatory response, often with the formation of “foreign-
body” type granulomas (Fig. 2), and progressive interstitial ﬁbrosis
that disrupt renal function. The interaction between calcium oxalate
crystals and the tubular epithelium seems to be enhanced by the ex-
pression of cell surface molecules such as CD44, hyaluronic acid and
osteopontin [71]. Although many aspects of the mechanism of tissue
damage in PH1 remain unknown, it seems that calcium oxalate crys-
tals [72] rather than the oxalate ion, at the levels found in the tubular
ﬂuid [73] are involved in tubular cell damage. In addition to direct tis-
sue damage by calcium oxalate crystals and inﬂammation, recurrent
urolithiasis, with frequent urinary tract obstructions and infections
complicate the condition to the point of ESRD. However, patients
with early diagnosis, good compliance to conservative treatmentG
T
gr
Fig. 2. Nephrocalcinosis. Renal parenchyma damage due to tubular and interstitial de-
position of calcium oxalate (arrow). Intense interstitial inﬂammatory reaction, with
formation of foreign-body type granulomas (gr), centered by giant cells engulﬁng cal-
cium oxalate crystals (inset) and surrounded by epithelioid histiocytes and a collar of
mononuclear leukocytes. Widespread interstitial inﬂammation leads to prominent tu-
bular atrophy (T) and glomerular ischemic changes (G).and speciﬁc genotypes that respond to vitamin B6 administration
(see below) may preserve stable renal function.
Once glomerular ﬁltration rate (GFR) falls below 30–40 mL/min
per 1.73 m2 body surface area, renal excretion of oxalate is insufﬁ-
cient to keep plasma oxalate concentration within the normal limits
(below 6 μmol/L [74]) and it can quickly exceed the supersaturation
threshold for plasma calcium oxalate, with levels above 30 μmol/L,
leading to widespread deposition of calcium oxalate (oxalosis). At
this stage, in addition to the kidney, many organs are damaged by cal-
cium oxalate crystals and the inﬂammatory response around them.
Retina, myocardium, vessel walls, skin, bone, and the central nervous
system are the main organs affected by oxalosis, and long-term com-
plications of PH include cardiomyopathy, cardiac conduction distur-
bances and heart block, vasculopathy, treatment-resistant anemia,
oxalate osteodystrophy, retinopathy and early death [17,18].
4. Clinical aspects of PH
Although the metabolic defects in PH is present from birth, there is
a striking variability in the age of presentation of symptoms, ranging
from severe infantile oxalosis (reported only in PH1) to adult presen-
tations that resemble idiopathic kidney stone disease [17,22].
The age of presentation is typically the ﬁrst decade, and the most
common ﬁrst symptoms are hematuria, abdominal pain, passage of
a stone or repeated urinary tract infections. In the more severe infan-
tile forms, patients present with signs and symptoms of renal failure
already, with failure to thrive, anemia and acidosis.
In adults, PH1 often goes unrecognized for years, with patients
considered to suffer idiopathic kidney stone disease, until severe kid-
ney damage (nephrocalcinosis) has already occurred [75].
Progressive renal interstitial inﬂammation and ﬁbrosis related to
the parenchymal calcium oxalate deposition, recurrent urolithiasis
and urinary tract infections, ultimately lead to ESRD and subsequent
systemic oxalosis. At this point, the diagnosis of PH may be over-
looked and ESRD attributed to idiopathic stone kidney disease. As
for PH2, a minority of patients (around 20%) develop ESRD, while
no progression to this stage has been reported for PH3.
In general, PH1 has a poor prognosis unless liver (and kidney)
transplantation are performed, mostly due to cardiovascular compli-
cations of systemic oxalosis after renal failure. In a recent analysis of
the European registries (ESPN/ERA-EDTA), among 9247 incident pe-
diatric patients that started renal replacement therapy (RRT) in the
1979–2009 period, 100 had PH, and their survival 5 years after the
start of RRT was only 76% [14]. This ﬁgure represents a three-fold
higher mortality than non-PH patients on RRT. For infantile PH1,
which is often diagnosed when the patient has lost renal function, a
survey of specialized centers worldwide showed 52% mortality: 82%
in developing countries vs. 33% in developed ones [76].
Early diagnosis and treatment are crucial for PH patients, as shown
by recent clinical studies that found median ages at ESRD above
30 years old now, while earlier series reported a 50% risk of ESRD by
the age 15, and about 80% by age 30 [21,22,77]. Although the mortal-
ity rate can be reduced, patients are still at high risk of developing
side effects of the symptomatic treatment. PH1 patients generally
have a poor quality of life unless liver–kidney transplantation is suc-
cessful. Even in this situation, the patient is dependent on immuno-
suppression and the life expectancy is signiﬁcantly reduced. Only
long term correction of the defect and prevention of kidney damage
can reasonably be expected to improve such consequences.
In contrast to PH1, which can be as severe as to cause ESRD in in-
fants, PH2 appears to have less severe tissue damage and better pres-
ervation of renal function over time [78]. Although the clinical
experience with patients diagnosed with PH3 mutations is still limit-
ed, it seems to be also milder than PH1, and high calcium and uric
acid, in addition to high oxalate, tend to be present in their urine
[66,69].
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Early diagnosis and therapy are crucial to preserve renal function
in PH patients and delay ESRD as much as possible. PH should be in-
vestigated in patients with nephrocalcinosis and kidney stone dis-
ease, after ruling out common causes of these entities. PH should
also be considered in all cases of familiar stone disease and renal fail-
ure of unknown cause.
Elevated urine oxalate (UOx) excretion>0.5 mmol/1.73 m2 per
day (typically >45 mg for an adult) is characteristic of PH, provided
that repeated measurements are consistent, and secondary hyperox-
aluria has been ruled out. In PH1 patients, overproduction of oxalate
by the liver results in very high urinary oxalate excretion, typically
>1 mmol/1.73 m2 per day, while less severe hyperoxaluria is normal-
ly found in PH2 and PH3 patients. Conﬁrmation of hyperoxaluria from
a 24 hour urine collection related to body surface area is recom-
mended. In children, where 24 hour urine collection is not practical,
oxalate/creatinine ratio can be determined on random urine speci-
mens. Ratios fall rapidly in early life and are inﬂuenced by prematuri-
ty and nutrition; thus interpretation requires an age-related reference
range [79]. A raised urine glycolate excretion is suggestive of PH1 but
it is elevated in only two thirds of patients and its levels vary depend-
ing on diet. Elevated L-glycerate is indicative of PH2.
Plasma oxalate (Pox) will increase as GFR falls, and the rate of in-
crease is much faster than in ESRD due to any other cause, with values
above 50, even 100 μmol/L.
The presence of abundant oxalate crystals in a renal biopsy is typ-
ical of PH (Fig. 2). Although calciﬁcations in tubular proﬁles can be
found in renal biopsies unrelated to PH, the presence of abundant
deposits, particularly if found in the interstitium, with strong in-
ﬂammatory reaction, should prompt further investigations.
Foreign-body type granulomas around calcium oxalate deposits
are strong indicators of PH. In some instances, the renal biopsy pro-
vides the ﬁrst clue for PH in patients that had been treated as com-
mon kidney stone disease sufferers or, more dramatically, after a
renal transplant with delayed function [19]. In these cases, oxalate
deposits appear rapidly in the transplanted kidneys and the organ
could be lost in weeks or a few months. In advanced cases of uremic
bone disease, with radiological evidences of osteitis ﬁbrosa and
osteosclerosis, the bone biopsymay provide the deﬁnitive diagnosis,
showing the typical granulomatous reaction surrounding oxalate
deposits.
The measurement of catalytic activities in a liver biopsy is consid-
ered the diagnostic gold standard, with a sensitivity>95% [80], al-
though false negatives are possible, given the wide range of residual
activity seen [39]. This is particularly relevant in the case of mistarget-
ing mutations, where AGT with signiﬁcant enzymatic activity is pre-
sent in the mitochondria. Part of the liver biopsy can be used for
immunohistochemical analysis, to ascertain subcellular localization,
and a small amount of tissue is enough for mRNA isolation, but
these techniques are not done routinely in most diagnostic
laboratories.
On the other hand, less invasive DNA analysis is becoming the ﬁrst
choice for diagnosis in most cases, and it is also used for prenatal test-
ing and diagnosis in other family members after the mutation is
known in the index case. In most hospitals, liver biopsy is currently
used only in patients for which no mutation is found in the AGXT,
GRHPR or HOGA1 genes, in order to completely exclude the known
variants of PH. There are isolated instances in which hyperoxaluria
is due to endogenous overproduction (PH), and the three known
genes have been ruled out, but the causal gene has not been found
yet. Genome-wide linkage studies are ongoing to try to map such
gene(s).
An algorithm to assist in diagnosis has been published [81] and
current European guidelines have been drafted by a panel of
experts.6. Prevention
All forms of PH described to date are hereditary, with an autoso-
mal recessive pattern of inheritance. Heterozygous carriers of the mu-
tated genes have, for the most part, no clinical signs or symptoms of
the disease. However, carriers of HOGA1mutations have been recent-
ly identiﬁed among patients with mild hyperoxaluria and urolithiasis
[66]. Genetic or presymptomatic counseling is only feasible after the
diagnosis of an index patient has been conﬁrmed in a family member.
7. Treatment
Conservative measures should be initiated as soon as possible
with the goal of preserving renal function. The following measures
apply to all types of PH with the exception of pyridoxine which is spe-
ciﬁc to PH1.
High ﬂuid intake has been proven to be effective in kidney stone
diseases [82]. In PH, the recommended ﬂuid intake is at least 3 L/m2
per day, distributed throughout 24 h. A feeding or gastrostomy tube
is often required in infants and small children to achieve this goal.
Special care should be taken in situations of ﬂuid losses (diarrhea,
vomiting, and fever) or limited oral hydration (surgery) and i.v.
ﬂuid intake might be necessary to keep high urine ﬂow. It is impor-
tant to realize that maintaining a high urine ﬂow is an efﬁcient way
to eliminate oxalate, while a temporary ﬂow reduction can lead to
calcium oxalate deposits that favor further aggregation of crystals.
7.1. Vitamin B6
PLP, a form of vitamin B6, is a cofactor for AGT. Administration of
pyridoxine hydrochloride has been known for a long time to be asso-
ciated with a decrease in urinary oxalate (UOx) in about 30% of pa-
tients with PH1 [83,84], but the cellular and molecular basis of
pyridoxine responsiveness is not completely understood. Indeed,
this is one of the most intriguing aspects of PH1, that has prompted
great hopes for a potential therapeutic effect based on chemical and
pharmacological chaperones (see below).
All PH1 patients should be tested for pyridoxine responsiveness,
and if responsive, treated until liver transplantation is performed,
even if undergoing haemodialysis (HD). The recommended starting
dose is 5 mg/kg per day, increasing in 5 mg/kg steps to a maximum
of 20 mg/kg body weight per day [85]. Responsiveness is currently
deﬁned by >30% decrease in UOx excretion after a test period of a
minimum of 3 months at maximum dose [12,17]. Since vitamin B6
is very safe, with a small risk of sensory neurotoxicity as the main
side effect, a trial of pyridoxine treatment should be performed in
most cases, and particularly in patients with missense mutations. A
subset of patients carrying one or two copies of G170R or F152I mu-
tations have been shown to respond best to pyridoxine [86,87].
Binding of PLP to AGT protein enhances its kinetic stability, in-
creasing its half-life for irreversible denaturation, as shown by differ-
ential scanning calorimetry (Fig. 3) and the improvement is highest
with some mutant forms of AGT, particularly those in the minor hap-
lotype, such as G170R and I244T, among others, although many mu-
tations tested and even wild type AGT also beneﬁt in their kinetic
stability upon PLP binding [45]. It is likely that the most relevant pa-
rameter to estimate the kinetic stability of cytosolic AGT folded di-
mers is the half-life for irreversible denaturation of the apo-forms.
Moreover, since PLP binding to AGT is a slow bi-molecular process
[3,45], and the total PLP concentration in liver is of the same range
of the total AGT concentration, an increase in cytosolic levels of free
PLP will signiﬁcantly speed up the formation of holo-proteins [45],
trapping the AGT in a folded and kinetically stable holo-form ready
for peroxisomal import. This is specially relevant for PH1 missense
mutations which are more destabilized in their apo-form than in
their holo-form. In this situation, PLP would preferentially stabilize
Fig. 3. Effect of PLP binding on the kinetic stability of dimeric AGT-His6 variants. A) Differential scanning calorimetry scans for holo (closed symbols) and apo (open symbols) var-
iants of wt (black), LM (dark red) and LRM (dark yellow). Lines are ﬁts to a two-state irreversible denaturation model. B) Plots of the natural logarithm of the ﬁrst-order rate con-
stants (k) for the irreversible denaturation of the AGT variants shown in panel A (Arrhenius plots). Note that the values of k extrapolated at physiological temperature are similar for
holo-LM and holo-LRM, while the k values for apo-LM indicate a higher kinetic stability (~25-fold) than the apo-LRM. The values of k corresponding to different half-lives (from
1 min to 1 year) are also indicated. C) Pictorial representation of the possible energetic impact of PLP binding on the free energy levels of the native state (NS) and the denaturation
transition state (TS), whose free energy differences (ΔG‡) determine the kinetic stability of AGT variants. Note that the ΔG‡ for apo-proteins decrease as follows: apo-wt>apo-
LM>apo-LRM variant, reﬂecting decreasing kinetic stabilities. However, PLP binding increases the ΔG‡ of holo-LRM more than for holo-LM, leading to similar kinetic stabilities
for these two variants as holo-proteins. wt = wild type major AGT; LM = minor AGT (with polymorphisms P11L and I340M); LRM = mutant G170R AGT in the minor haplotype;
PLP = pyridoxal phosphate; apo- = AGT without PLP cofactor; holo- = AGT with PLP cofactor.
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reversible denaturation (Fig. 3C).
Alkalinization of the urine with alkali citrate can reduce urinary
CaOx saturation. Liver conversion of citrate to bicarbonate leads to
higher urinary pH and subsequent increase in citrate excretion. Cit-
rate then forms complexes with calcium, decreasing CaOx precipita-
tion [88]. Potassium citrate (or sodium citrate, depending on renal
function and serum potassium) at a daily dose of 0.10–0.15 g/kg
body weight is recommended.
7.2. Diet
The main source of oxalate in PH is the endogenous production by
the liver, making strict dietary restrictions on oxalate-containing
foods unnecessary. In fact, intestinal oxalate absorption is lower in
PH patients compared to normal subjects [15]. Calcium intake should
remain normal as oral calcium binds intestinal oxalate and dietary
calcium restriction results in higher oxalate intestinal absorption[89,90]. Excessive intake of vitamins C and D is to be avoided, and vi-
tamin D supplementation in children should be used carefully. Given
the high hydroxyproline content of gelatin and meats, it seems rea-
sonable to advice their consumption reduction among PH patients,
particularly PH3, but no formal recommendation has been included
in clinical guidelines.
7.3. Dialysis
Both peritoneal dialysis (PD) and hemodialysis (HD) have been
used either alone or in combination in order to maximize oxalate re-
moval [91,92]. Oxalate is a small molecule (90 Da) that can be ﬁltered
readily, but oxalate is produced by the PH liver at a daily rate higher
(4–7 mmol/1.73 m2 per day) than the oxalate removing capacity of
dialysis (1–4 mmol/1.73 m2), resulting in oxalate accumulation
[91,93]. Thus, dialysis is used while waiting for organ transplantation
or achieving adequate body size, but it is not adequate replacement
therapy for patients with systemic oxalosis who have reached ESRD
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tween 30 and 45 μmol/L, also depending on serum calcium concen-
tration [74,95]. Intensive dialysis is needed to lower plasma oxalate
(POx) enough to keep βCaOx b1 as long as possible during the inter-
dialytic period. Although a HD session can reduce POx by about 60%,
oxalate turnover from tissue deposits and endogenous oxalate pro-
duction bring POx back to 80% of the pre-dialysis levels within 24 h
[96].
7.4. Transplantation
Once a ﬁrm diagnosis of PH1 is established, organ transplantation,
replacing the oxalate-producing liver with a donor organ, should be
planned and best results are achieved if this occurs before systemic
oxalosis. The strategy of liver–kidney transplantation is inﬂuenced
by the stage of the disease [97]. Pre-emptive isolated liver transplan-
tation (LTx) may be an option in selected patients [98,99] but in most
cases, the liver is replaced only after sufﬁcient kidney damage has oc-
curred, opting for combined liver–kidney transplantation (LKTx).
LKTx has been used successfully with excellent outcome even in
small infants [100,101]. A sequential procedure (ﬁrst liver transplan-
tation, then dialysis until sufﬁcient oxalate has been cleared from the
body, followed by kidney transplantation) may be proposed in indi-
vidual ESRD patients.
Isolated kidney transplantation might be a solution in some pa-
tients with good response to conservative measures and vitamin B6
administration, but it is not recommended in the majority of PH1 pa-
tients, given the high risk of quick deterioration of the renal allograft,
still overloaded with oxalate produced by the PH1 liver [19]. In milder
PH variants (most cases of PH2, and probably PH3), kidney transplan-
tation might be sufﬁcient to control the disease, but there are not
evidence-based guidelines available yet.
8. Prospects for molecular therapy
Signiﬁcant advances in the pathophysiology of PH in the last cou-
ple of decades have led to better diagnosis and treatment of these pa-
tients, but current therapeutic options are far from ideal. The risks
associated with liver transplantation (survival rates of 86 and 69% at
1 and 10 years, respectively [102]) make it difﬁcult, for patients, fam-
ilies and doctors, to go ahead and replace an otherwise healthy liver
from a PH1 patient in order to save the kidneys. Thus, LTx is usually
delayed until complicating renal failure necessitates LKTx [103]. In
addition, there are signiﬁcant health risks associated to long-term im-
munosuppression, with 13% and 31% of patients reaching stage 3
chronic kidney disease at 5 and 10 years after LTx, respectively
[104]. The situation in PH1 is even worse [105], most likely due to
the synergistic nephrotoxic effect of immunosuppression and oxalate.
Although PH is a rare disease, there is considerable interest in
translating the recent advances in the understanding of the molecular
mechanisms of disease into better targeted therapies [106]. Some of
these efforts can be implemented in vitro, but the development of ge-
netic animal models for PH [107] (and unpublished) has provided ex-
cellent testing grounds for in vivo experimentation.
8.1. Oxalate degrading enzymes
Oxalate cannot be metabolized in mammals, but other forms of life
have enzymes such as oxalate oxidase and oxalate decarboxylase, ca-
pable of degrading oxalate. These enzymes have been investigated as
a novel solution to oxalate accumulation in PH. It has also become
clear that some oxalate can be eliminated by the gastrointestinal
tract, using the anion exchanger SLC26A6 [108], and this route
could be relevant when renal function deteriorates. A mouse
Slc26A6 deﬁcient model has been shown to develop severe hyperox-
aluria [109], bringing more attention to this potential therapeutictarget, although signiﬁcant differences between human SLC26A6
and its rodent counterpart have to be considered [110]. Recombinant,
stabilized, oxalate oxidase has been tested in hyperoxaluric mice,
showing a signiﬁcant reduction in urine oxalate excretion [111].
Strategies to increase oxalate degradation by gut colonization with
the oxalate-metabolizing bacteria Oxalobacter formigenes have
shown promising results in the mouse PH1 model [112] and in
some pilot studies with PH1 patients [113], but a consistent beneﬁt
derived from the use of probiotics with O. formigenes to reduce oxa-
late load in PH1 patients could not been demonstrated so far [114],
and new delivery options continue being investigated.
8.2. Enzyme replacement therapy (ERT)
Remarkable improvements have been achieved by ERT in some in-
born errors of metabolism, particularly the lysosomal storage diseases
[115]. This approach has not been tested in PH, deterred by the very
signiﬁcant challenges unique to PH1. The fact that any hepatocyte
that is not corrected will continue producing oxalate poses an impor-
tant limitation to strategies aimed at correcting hepatocytes by deliv-
ery of enzymes or genes. In addition, proteins are taken up by
hepatocytes via endosomes, and the replaced AGT would have to be
efﬁciently targeted to the peroxisome. Advances in the ﬁeld of cell-
penetrating peptides and subcellular targeting could bring the ERT
option to the PH testing arena in the future.
8.3. Gene therapy (GT)
After years of ups and downs in the ﬁeld, recent developments
have provided renewed optimism for approaches to treat hereditary
enzyme deﬁciencies by providing the normal sequence of the gene
to the key defective cells [116]. Again, in a disease like PH, where
non-transduced hepatocytes would continue to produce oxalate, the
therapeutic goal can only be achieved if sufﬁcient hepatocytes are
transduced so that the overall production of oxalate by the treated
liver remains below the capacity of the kidneys to excrete it without
suffering irreversible damage. The development of viral vectors with
enhanced hepatocyte tropism and minimal immune response results
in high proportions of hepatocytes showing sustained expression
levels, making gene therapy a realistic option for PH in the future. In
fact, using adenoassociated viral particles, the treatment of the PH1
mouse model has been quite successful [117].
8.4. Substrate reduction therapy (SRT)
The main sources of glyoxylate are glycine, glycolate and hydroxy-
proline, in metabolic reactions catalyzed by enzymes such as D-
amino oxidase (DAO), glycolate oxidase (HAO1) and 4-hydroxy-2-
oxoglutarate aldolase (HOGA1). Thus, a therapeutic strategy to
ameliorate glyoxylate build-up in PH patients would be to inhibit
any non-essential pathway leading to glyoxylate. The idea of inhibit-
ing HAO1 as substrate reduction therapy is anything but new. The
structure of the spinach homolog of human HAO1 has been available
for years, and small molecule inhibitor of this enzyme had been
found, but the results of a pilot study in PH1 patients were disap-
pointing [118]. The biochemical and structural properties of human
HAO1 has been described recently [119,120]. It seems plausible that
renewed attempts to inhibit HAO1 with increasing speciﬁcity will
eventually result in a useful SRT for PH1. In addition to increased
speciﬁcity of the small molecules, avoiding inhibition of other FMN-
dependent enzymes, for this SRT strategy to be safe HAO1 must
play non-essential roles in human cell metabolism. Using genetically
modiﬁed mice, we have observed that Hao1 deﬁcient mice are
healthy and the introduction of this second KO gene in the PH1
mouse model results in a dramatic reduction in urinary oxalate excre-
tion (manuscript in preparation). Metabolic differences between
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these results, but the data currently available points to HAO1 as a
good target for SRT in PH1.
In theory, DAO could also be a potential target for SRT, and there is
interest in the pharmaceutical industry to develop DAO inhibitors,
given the implications of this enzyme in mental diseases [121].
With recent evidence that hydroxyproline is an important source
of glyoxylate in humans [5], and the discovery of HOGA1 as the
gene responsible for PH3 [69], this pathway is increasingly attractive
as a target for SRT. Two enzymes are speciﬁc to hydroxyproline deg-
radation: hydroxyproline dehydrogenase (oxidase) (PRODH2) and
HOGA1. Although HOGA1 seemed a plausible target at ﬁrst, recent
evaluation of mutations in PH3 patients indicates that inhibiting
HOGA1 would increase, rather than decrease, oxalate production.
On the other hand, PRODH2, the ﬁrst enzyme in the mitochondrial
hydroxyproline degradation pathway remains a good candidate for
SRT in PH in general, and PH3 in particular. By using genetically mod-
iﬁed mice, we are currently testing whether PRODH2 is a safe and ef-
ﬁcient target.
8.5. Chemical chaperone and proteostasis regulation therapy (CC–PRT)
“Proteostasis” is an integrative deﬁnition of protein intracellular
homeostasis which combines concepts from protein folding and sta-
bility, cellular macromolecular assemblies assisting protein folding,
degradation and intracellular trafﬁcking, and systems regulating pro-
tein expression and function at transcriptional, translational and
post-translational levels. This complex and highly regulated network
determines the intracellular fate of proteins [47,122]. Recent studies
have shown that AGT native state kinetic stability [45,46] and interac-
tions of partially folded states with molecular chaperones such as
Hsp40/DnaJ (unpublished), Hsp60/GroEL, Hsc70 and Hsp90
[38,45,123] may be involved in the partition of AGT protein between
correctly folded dimers and misfolding, with mitochondrial mistar-
geting, aggregation and degradation.
Therefore, several proteostasis elements emerge as potential tar-
gets for therapeutic intervention in PH1. Moreover, a recent report
suggest that the cytosolic levels of folded AGT may be a relevant fac-
tor determining the efﬁciency of its peroxisomal import, due to the
very low afﬁnity displayed for the PEX5 receptor compared to other
peroxisomal proteins [33].
Pharmacological modulation of molecular chaperones is a promis-
ing therapeutic strategy in several conformational diseases [124]. The
canonical model for the HSP70 machinery has been elucidated with
great detail in prokaryotes, but the system is much more complex in
humans, displaying at least 11 HSP70s, 41J-proteins and 13 nucleo-
tide exchange factors (NEFs) [125]. In addition, mammalian J-
proteins and NEF proteins are structurally and functionally complex,
displaying additional functions beyond the canonical model. For in-
stance, J-proteins are known to be involved in shunting client pro-
teins for degradation, remodeling and partially unfolding client
proteins, while the BAG (BCL2-associated athanogene) family of
NEFs are also known to target client proteins for proteasomal degra-
dation [125]. Therefore, ﬁnding targets in the HSP70 machinery for
therapeutic intervention in PH1 requires an exhaustive biochemical
and cellular research on all these targets to determine those respon-
sible for mitochondrial mistargeting, aggregation and degradation.
A different approach to treat PH1 could be based on the kinetic
stabilization of the AGT native state with pharmacological or chemical
chaperones. Pharmacological chaperones are small-molecules which
speciﬁcally bind to the protein native state leading to either thermo-
dynamic or kinetic stabilizations. PLP (see above) is a special case of
natural kinetic stabilizer of AGT (Fig. 3) [35,45]. However, the basic
mechanism of PLP kinetic “overstabilization” of missense mutations
is not fully understood. According to the transition state theory, dena-
turation rates are determined by the activation free energy, the freeenergy difference between the native and the unfolding transition
state (which is the unfolding rate limiting step and not directly acces-
sible to investigation). Thus, PLP binding must increase the unfolding
free energy barrier in some mutations compared to the wild type en-
zyme. Our previous analyses have shown that PLP induced notable ki-
netic stabilization of wild type AGT, increasing the unfolding free
energy barrier by 6–7 kcal/mol at 37 °C, but still lower than the free
energy of PLP bound to the native state (around 10 kcal/mol at phys-
iological temperature [45]). This suggests that PLP remains bound to
the unfolding transition state but possibly with lower afﬁnity. Thus,
it is plausible that PLP binding partially overcome mutation-induced
destabilization of the native state, while these PLP effects are margin-
al or not observed at all in the unfolding transition state. The unfold-
ing transition states for these mutants might show some distortion in
PLP binding compared to the wild type protein. Nevertheless, a
throughout investigation of mutational effects on the structure and
energetics of the native and transition states must be carried out to
dissect these differences found between holo- and apo-AGT in some
variants, as well as to evaluate the impact of mutations at different
AGT domains and structural positions.
Protein stabilization is easily adapted to high-throughput screen-
ing of chemical libraries based on a thermal up-shift assay to ﬁnd
potential pharmacological chaperones [126]. In some cases,
pharmacological chaperones resemble known protein ligands or in-
hibitors, and their stabilizing effect may be enhanced by structure-
based approaches [127]. The efﬁcacy of pharmacological chaperones
may be sensitive to mutations, since they may affect binding afﬁni-
ties, folding/unfolding mechanisms and interactions with the pro-
teostasis network. Consequently, pharmacological chaperones have
been shown to correct protein misfolding in several genetic diseases
and it seems likely that missense PH1 mutations can beneﬁt from
this approach in the future. Chemical chaperones are small organic
compounds which favor compact protein states over unfolded states
through the so-called “solvophobic effect”, which involves destabiliz-
ing interactions of the water/chaperone mixture with the polypeptide
backbone [128]. Their beneﬁcial effect on mutant AGT has been dem-
onstrated in vitro, [38,49] but the main drawback of these compounds
are the high concentrations required for protein stabilization and the
unspeciﬁcity of the stabilizing effect, potentially affecting the physio-
logical turnover of multiple proteins.
8.6. Cell therapy (CT)
Liver transplantation has changed dramatically the outcome of
many inborn errors of liver metabolism [129], and PH1 is a good ex-
ample. However, the morbidity and mortality associated with this
procedure is signiﬁcant, and alternatives to total liver transplantation
have been explored in order not to make the recipient's life absolutely
dependent on the metabolic competence of the allograft. But partial
liver transplantations have failed to provide enough reduction of ox-
alate production in PH1 [102]. Hepatocyte cell transplantation is a
promising alternative that is being actively explored in inborn errors
of liver metabolism [130], including PH1, at the experimental level
[131,132].
Hepatocyte transplantation is a minimally invasive procedure, al-
though the number of mature hepatocytes that can be safely injected
in one session is not enough to treat standard autosomal recessive en-
zymatic deﬁcits [133], and probably less so for PH1 in particular.
In cases when the healthy hepatocytes from the donor have a se-
lective advantage over the recipient ones, the regenerative potential
of hepatocytes can be used to achieve gradual repopulation of the
liver, an approach that has been successful in mouse model of hered-
itary tyrosinaemia type I [134]. Interestingly, this model has been im-
proved to be able to use induced pluripotent stem cells (iPS) derived
from ﬁbroblasts, to generate the hepatocyte-like cells that could be
transplanted to repopulate the diseased liver [135]. A major obstacle
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produce large amounts of oxalate but do not seem affected by it, and
they are not at a selective disadvantage with respect to the trans-
planted cells. From our gene therapy experiments with the PH1
mouse model, we calculated that around 40% hepatocytes need to
be transduced with the wild type gene to revert the hyperoxaluric
phenotype [117]. Replacing a similar proportion of hepatocytes,
which in the human liver would represent about 2×1010 cells, cannot
be achieved without manipulations that provide selective advantage
to the transplanted cells. In previous experimental studies, we have
shown that liver irradiation can be used to limit the regenerative ca-
pacity of the endogenous hepatocytes, selecting for the transplanted
cells to be the only ones responding to proliferative stimulus, and
repopulating the liver over time [131,132]. Alternative methods,
based on pro-drugs that become hepatotoxic only after reacting
with high levels of cytoplasmic glyoxylate would be useful.
Combining the concepts of gene and cell therapy, one can envi-
sion a situation in which iPS cells can be derived from PH1 ﬁbro-
blasts, their AGXT gene corrected in vitro, and later differentiated
into hepatocytes for autologous cell transplantation. The gene cor-
rection part of the procedure could be implemented with novel
nuclease-based targeted strategies [136], avoiding the need to
rely on homologous recombination for gene correction, and open-
ing the possibilities to efﬁcient gene correction in non-ES cell
types, such as ﬁbroblasts, as recently shown in mouse experimen-
tal models [137].
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